Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) have earned an average recommendation of "Moderate Buy" from the nine ratings firms that are covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $16.75.

FOLD has been the topic of a number of research analyst reports. StockNews.com downgraded shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday, February 20th. Needham & Company LLC reiterated a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. JPMorgan Chase & Co. raised their price target on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 12th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $21.00 price objective on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Finally, Morgan Stanley reiterated an "equal weight" rating and issued a $12.00 price objective (down from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th.

Remove Ads

Amicus Therapeutics Stock Down 1.8 %

FOLD traded down $0.16 during trading hours on Thursday, reaching $8.86. 2,019,097 shares of the stock traded hands, compared to its average volume of 2,323,927. The firm's fifty day simple moving average is $9.43 and its two-hundred day simple moving average is $10.25. The company has a market cap of $2.72 billion, a price-to-earnings ratio of -49.22, a PEG ratio of 1.51 and a beta of 0.69. Amicus Therapeutics has a fifty-two week low of $8.78 and a fifty-two week high of $12.65. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42.

Hedge Funds Weigh In On Amicus Therapeutics

Several hedge funds have recently made changes to their positions in FOLD. Old West Investment Management LLC grew its stake in shares of Amicus Therapeutics by 617.2% in the 3rd quarter. Old West Investment Management LLC now owns 340,441 shares of the biopharmaceutical company's stock worth $3,636,000 after purchasing an additional 292,976 shares during the last quarter. Los Angeles Capital Management LLC grew its stake in shares of Amicus Therapeutics by 46.3% in the 3rd quarter. Los Angeles Capital Management LLC now owns 20,474 shares of the biopharmaceutical company's stock worth $219,000 after purchasing an additional 6,484 shares during the last quarter. GSA Capital Partners LLP grew its stake in shares of Amicus Therapeutics by 163.8% in the 3rd quarter. GSA Capital Partners LLP now owns 133,800 shares of the biopharmaceutical company's stock worth $1,429,000 after purchasing an additional 83,081 shares during the last quarter. OLD Second National Bank of Aurora acquired a new position in shares of Amicus Therapeutics in the 3rd quarter worth approximately $26,000. Finally, Tokio Marine Asset Management Co. Ltd. acquired a new position in shares of Amicus Therapeutics in the 3rd quarter worth approximately $113,000.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.